Release date: 2007-08-17

Chinese medical equipment firms are facing a "double anemia" challenge, caught between the pressure of foreign competition and the lack of technological innovation and brand strength. Despite the rapid growth of China's medical equipment market in recent years, the industry's total output value only accounts for about 2% of the global market. While China is seen as one of the most promising markets globally, domestic companies have struggled to grow steadily, often finding themselves at a disadvantage compared to international players. According to forecasts from authoritative organizations, the Chinese medical equipment market is expected to grow by around 14% annually over the next few years, with high-end equipment sales projected to rise by as much as 20%. Industry experts estimate that this year alone, sales in the sector could reach 40 billion yuan, with the overall market size potentially reaching between 50 and 55 billion yuan. Despite these positive projections, foreign capital and joint ventures have taken control of the majority of the domestic market. In the top 10 medical equipment companies in China, seven are either foreign-owned or joint ventures. Among the top 50, foreign and joint venture firms account for more than half of both revenue and profits. This dominance makes it difficult for local companies to gain a foothold. At a recent seminar on the current status and future direction of China's medical equipment industry, experts highlighted the challenges faced by domestic firms, particularly in the field of medical diagnostic equipment. Most large-scale diagnostic systems are still imported from Europe and the U.S., with many Chinese companies only acting as agents. This arrangement leaves them without access to core technology or brand ownership, making them dependent on foreign suppliers for pricing, supply, and cooperation terms. This dependency has led to intense competition among Chinese companies, with some struggling to maintain stable relationships with foreign partners while dealing with unreasonable demands. As a result, many firms are forced to compete at the lower end of the value chain, lacking both advanced technology and strong branding. A representative from the China Medical Device Industry Association noted that the industry started late, operates on a small scale, and lacks sufficient investment and market share. These factors make it challenging to compete with global giants. However, there is hope. In recent years, some Chinese companies have made significant progress. Some have increased R&D spending, while others have invested heavily in acquiring technology and brands. For example, Shenzhen Saile, one of China’s largest providers of enzyme-free equipment, has successfully transitioned from a distributor to a full-service supplier by acquiring a majority stake in XIRIL, a leading global medical device company. This move was made possible through strategic equity swaps and leveraging its market presence, sales network, and financial resources. This shift highlights the potential for Chinese firms to break free from their traditional roles and build stronger, more independent positions in the global medical equipment industry. —— Source: Shanghai Medical Device Industry Association Network

Anti-Diabetes

Diabetes is a group of metabolic diseases characterized by high blood sugar. Hyperglycemia is due to insulin secretion defects or their biological effects of damage, or both caused. Hyperglycemia in long-term diabetes, leading to various tissues, especially the eyes, kidneys, heart, blood vessels, nerve chronic damage, dysfunction. The etiology of diabetes is roughly one is Genetic factors. Type 1 or type 2 diabetes had significant genetic heterogeneity. There is a family history of diabetes mellitus, 1/4 ~ 1/2 patients with family history of diabetes. Clinically at least 60 kinds of genetic syndromes may be associated with diabetes. Second, Environmental factors, eating too much, reduce physical activity caused by obesity is the most important environmental factors of type 2 diabetes, so that type 2 diabetes genetic susceptibility to individuals prone to disease. There is no cure for diabetes, but through a variety of treatment can control diabetes. Mainly includes five aspects: diabetes education, self-monitoring of blood sugar, diet therapy, exercise therapy and drug treatment. Antidiabetic drugs are needed in the patient after eating and exercise therapy and diabetes health education, blood sugar control can not be achieved when the target treatment. Most antidiabetic drugs have a greater side effect, so the patient must follow the doctor's instructions. With the succession of new antidiabetic drug patents,the patient is not only actually reducing the cost of treatment, but also increased the number of treatment options, Take greater hopes to patients with disease control.

Anti-Diabetes Intermediate,Diabetes Mellitus,Diabetic Drugs,Newer Antidiabetic Drugs

Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com